A REVIEW OF KETAMINE ABUSE AND DIVERSION

Depression and Anxiety

Volumn 33, Issue 8, 2016, Pages 718-727

  Sassano Higgins, Sean ^a,b   Baron, Dave ^a,b   Juarez, Grace ^a,b   Esmaili, Neevon ^b   Gold, Mark ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Rivermend Health LLC   (United States)

^c Scientific Advisory Boards   (United States)

Author keywords

delirium; depression; dissociative disorders; ketamine; phencyclidine; substance related disorders

Indexed keywords

DESIGNER DRUG; DEXTROMETHORPHAN; DOPAMINE; ILLICIT DRUG; KETAMINE; MU OPIATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RECREATIONAL DRUG;

ABDOMINAL PAIN; ASTHMA; BILE DUCT DILATATION; BLURRED VISION; BRADYCARDIA; CHRONIC PAIN; COCAINE DEPENDENCE; COGNITIVE DEFECT; COLIC; COMMON BILE DUCT CYST; CONCENTRATION LOSS; COORDINATION DISORDER; CYSTITIS; DELIRIUM; DELUSION; DEPRESSION; DIZZINESS; DRUG ABUSE; DRUG ABUSE PATTERN; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG METABOLISM; DRUG OVERDOSE; DRUG TOLERANCE; DRUG TRAFFIC; DRUG WITHDRAWAL; DYSURIA; ELIMINATION HALF-LIFE; HALLUCINATION; HEADACHE; HEART VENTRICLE EXTRASYSTOLE; HEMATURIA; HUMAN; HYPERTENSION; HYPOTENSION; LIVER DISEASE; LOWER URINARY TRACT SYMPTOM; MEMORY DISORDER; MENTAL DISSOCIATION; NAUSEA; NIGHTMARE; NONHUMAN; PAIN; PERCEPTION DISORDER; PHARMACODYNAMICS; POSTOPERATIVE PAIN; PRESCRIPTION DRUG DIVERSION; PREVALENCE; PRIORITY JOURNAL; REINFORCEMENT; RESTLESSNESS; REVIEW; SEDATION; SIDE EFFECT; STOMACH DISEASE; SUPRAPUBIC PAIN; TACHYCARDIA; TREATMENT RESISTANT DEPRESSION; URGE INCONTINENCE; URINARY FREQUENCY; URINARY URGENCY; VISUAL DISORDER; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 84979671270     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22536     Document Type: Review

References (142)

1. FDA. Ketamine abuse. FDA Drug Bull 1979;9:24.
2. Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth 1989;36:186–197.
3. Haas DA, Harper DG. Ketamine: a review of its pharmacological properties and use in ambulatory anesthesia. Anesth Prog 1992:39:61–68.
4. Ketamine Jansen KL. Can chronic use impair memory? Int J Addict 1990;25:133–139.
5. Jansen KL. A review of the nonmedical use of ketamine: use, users and consequences. J Psychoactive Drugs 2000;32:419–433.
6. Mazzeffi M, Johnson K, Paciullo C. Ketamine in adult cardiac surgery and the cardiac surgery intensive care unit: an evidence based clinical review. Ann Card Anaesth 2015;18:202–209.
7. Ketamine Bergman SA. Review of its pharmacology and its use in pediatric anesthesia. Anesth Prog 1999;46:10–20.
8. Stewart KG, Rowbottom SJ, Aitken AW, et al. Oral ketamine premedication for pediatric cardiac surgery-a comparison with intramuscular morphine (both after oral trimeprazine). Anaesth Intensive Care 1990;18:11–14.
9. Wang HS, Cinelli AB, Pugh GB, Rock CK. Ketamine anesthesia in pediatric ophthalmic office procedures. Ann Ophthalmol 1990;22:26–29.
10. Green SM, Johnson NE. Ketamine sedation for pediatric procedures: part 2, review and implications. Ann Emerg Med 1990;19:1033–1046.
11. Green SM, Krauss B. The semantics of ketamine [editorial]. Ann Emerg Med 2000;36:480–482.
12. Dobbs T. Report: after patient death, UVM medical center waited weeks to fix flawed systems. VPR, July 7, 2015.
13. Green SM, Roback MG, Kennedy RM, Krauss B. Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update. Ann Emerg Med 2011;57:449–461.
14. White PF, Ham J, Way WL. Pharmacology of ketamine isomers in surgical patients. Anesthesiology 1980;52:231–239.
15. Domino EF, Chodoff P, Corssen G. Pharmacologic effects of Ci-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther 1965;6:279–291.
16. Sener S, Eken C, Schultz CH, et al. Ketamine with and without midazolam for emergency department sedation in adults: a randomized controlled trial. Ann Emerg Med 2011;57:109–114.
17. Fine J, Weissman J, Finestone SC. Side effects after ketamine anesthesia: transient blindness. Anesth Analg 1974;53:72–74.
18. Siegel RK. Phencyclidine and ketamine intoxication: a study of four populations of recreational users. NIDA Res Monogr 1978;21:119–147.
19. Jansen KL. Non-medical use of ketamine. BMJ 1993;306:601–602.
20. Dalgarno PJ, Shewan D. Illicit use of ketamine in Scotland. J Psychoactive Drugs 1996;28:191–199.
21. Dotson JW, Ackerman DL, West LJ. Ketamine abuse. J Drug Issues 1995;25:751–757.
22. Smith KM. Drugs used in acquaintance rape. J Am Pharm Assoc 1999;39:519–525.
23. Krystal JH, Karper LP, Seibyl JP, et al. Subanaesthetic effects of the noncompetitive NMDA anatgonist, ketamine, in humans. Arch Gen Psychiatry 1994;51:199–214.
24. Oranje B, van Berckel BN, Kemner C, et al. The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology 2000;22:293–302.
25. Hartvig P, Valtysson J, Lindner KJ, et al. Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers. Clin Pharmacol Ther 1995;58:165–173.
26. White PF, Way WL, Trevor AJ. Ketamine: its pharmacology and therapeutic uses. Anaesthesiology 1982;56:119–136.
27. Malhotra AK, Pinals DA, Weingariner H, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996;16:120–125.
28. Newcomber JW, Farber NB, Jevtovic-Todorovic V, et al. Ketamine induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999;20:106–118.
29. Hetem LA, Danion JM, Diemunsch P, et al. Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers. Psychopharmacology 2001;22:59–72.
30. Weiner AL, Vieira L, McKay CA, Bayer MJ. Ketamine abusers presenting to the emergency department: a case series. J Emerg Med 2000;18:447–451.
31. Bowdle TA, Radant AD, Cowley DS, et al. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anaesthesiology 1998;88:82–88.
32. EMCDDA. Report on the risk assessment of ketamine in the framework of the joint action on new synthetic drugs. Luxembourg: Office for Official Publications of the European Communities; 2002.
33. Graeme KA. New drugs of abuse. Pharmacol Adv Emerg Med 2000;18:625–636.
34. Barrett SP, Gross SR, Garand I, Pihl RO. Patterns of simultaneous polysubstance use in Canadian rave attendees. Subst Use Misuse 2005;40:1525–1537.
35. Bokor G, Anderson PD. Ketamine: an update on its abuse. J Pharm Practice 2014;27:582–586.
36. AIHW (Australian Institute of Health and Welfare). 2007 National Drug Survey Household Survey: Detailed Findings. Canberra: Author; 2008.
37. SAMSHA (Substance Abuse and Mental Health Services Administration). The NSDUH Report: Use of Specific Hallucinogens 2006. Rockville, MD: Author; 2008.
38. Paglia-Boak A, Mann RE, Adlaf EM, Rehm J. Drug Use among Ontario Students, 1977-2009: Detailed OSDUHS Findings. Toronto, Ontario: Centre for Addiction and Mental Health; 2009.
39. Hoare J, Moon D, editor. Drug misuse declared: findings from the 2009/10 British Crime Survey England and Wales. In: Home Office Statistical Bulletin. London: Home Office; 2010:1–109.
40. Kubota R, Komiyama T, Miwa Y, et al. Pharmacokinetics of ketamine and norketamine after oral administration of a liquid formulation of ketamine. J Curr Surg 2013;3:82–86.
41. Jantzen JP, Erdmann K, Hilley D, et al. Comparative study of analgesia and plasma level following rectal, intramuscular and intravenous administration of ketamine. Anaesthesist 1985;34:346–351.
42. Mion G, Villevieille T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Therapeut 2013;19:370–380.
43. Grant IS, Nimmo WS, Clements JA. Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br J Anaesth 1981;53:805–809.
44. Domino EF, Domino SE, Smith RE. Ketamine kinetics in unpremedicated and diazepam premedicated subjects. Clin Pharmacol Ther 1984;36:645–653.
45. Amiot JF, Roessler JG, Amadea B, et al. Anaesthesia with oral ketamine. Cah Anaesthesiol 1987;35:203–205.
46. Wieber J, Gugler R, Hengstmann JG, Dengler HJ. Pharmacokinetics of ketamine in man. Anaesthesist 1975;24:260–263.
47. Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2002;7:853–867.
48. Yanagihara Y, Kariya S, Ohtani M, et al. Involvement of CYP2B6 in N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2001;6:887–890.
49. Lindefors N, Barati S, O'Connor WT. Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex. Brain Res 1997;759:205–212.
50. Nishimura N, Sato K, Okada T, et al. Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells. Anesthesiology 1998;88:768–774.
51. Crisp T, Perrotti JM, Smith DL, et al. The local monoaminergic dependency of spinal ketamine. Eur J Pharmacol 1991;194:167–172.
52. Finck AD, Samaniego E, Ngai H. Morphine tolerance decreases the analgesic effects of ketamine in mice. Anesthesiology 1988;68:397–400.
53. Shimoyama M, Shimoyama N, Gorman AL, et al. Oral ketamine is antinociceptive in the rat formalin test: role of the metabolite, norketamine. Pain 1999;81:85–93.
54. Hansen G, Jenson SB, Chandresh L, et al. The psychotropic effect of ketamine. J Psychoactive Drugs 1988;20:419–425.
55. Curran HV, Morgan C. Cognitive dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addiction 2000;95:575–590.
56. Curran HV, Monaghan L. In and out of the k-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction 2001;96:749–760.
57. Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role on N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 1992;260:1209–1213.
58. Sinner B, Graf BM. Ketamine. Handb Exp Pharmacol 2008;182:313–333.
59. Dillon P, Copeland J, Jansen K. Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend 2003;69:23–28.
60. Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 2011;14:1127–1131.
61. aan het Rot M, Zarate CA, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? Biol Psychiatry 2012;72:537–547.
62. Lapidus, KA, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry 2014;76:970–976.
63. Chilukuri H, Reddy NP, Pathapati RM, et al. Acute antidepressant effects of intramuscular versus intravenous ketamine. Ind J Psychol Med 2014;36:71–76.
64. Blier, P, Zigman D, Blier J. On the safety and benefits of repeated intravenous injections of ketamine for depression. Biol. Psychiatry 2012;72:e11–e12.
65. Murrough, JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment resistant major depression. Biol Psychiatry 2013;74:250–256.
66. Szymkowicz SM, Finnegan N, Dale RM. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment resistant depression. J Affect Disord 2013;147:416–420.
67. Diamond PR, Farmery AD, Atkinson S, et al. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol 2014;28:536–544.
68. Segmiller, F, Ruther T, Linhardt A, et al. Repeated S-ketamine infusions in therapy resistant depression: a case series. J Clin Pharmacol 2013;53:996–998.
69. Shiroma PR, Johns B, Kuskowsko M, et al. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord 2014;155:123–129.
70. Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant depression: a two-site randomized controlled trial. Am J Psychiatry 2013;170:1134–1142.
71. Harihar C, Dasari P, Srinivas JS. Intramuscular ketamine in acute depression: a report on two cases. Indian J Psychiatry 2013;55:186–188.
72. Lara DR, Bisol LW, Munari LR. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol 2013;16:2111–2117.
73. Clark P. Treatment-refractory depression: a case of successful treatment with intranasal ketamine 10%. Ann Clin Psychiatry 2014;26:145.
74. aan het Rot, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010;67:139–145.
75. Paslakis G, Gilles M, Meyer-Lindenberg AM, Deuschle M. Oral administration of the NMDA receptor antagonist S-Ketamine as add-on therapy of depression: a case series. Pharmacopsychiatry 2009;43:33–35.
76. Luckenbaugh DA, Niciu MJ, Ionescu DF, et al. Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord 2014;159:56–61.
77. Dakwar E, AnerellaC, Hart CL, et al. Therapeutic infusions of ketamine: do the psychoactive effects matter? Drug Alcohol Depend 2014;136:153–157.
78. Dakwar E, Hart CL, Levin FR, et al. Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, crossover trial. Mol Psychiatry 2016. doi: 10.1038/mp.2016.39. [Epub ahead of print].
79. Visser E, Schuga SA. The role of ketamine in pain management. Biomed Pharmacother 2006;60:341–348.
80. Persson J. Ketamine in pain management. CNS Neurosci Ther 2013;19:296–402.
81. Zanicotti CG, Perez D, Glue P. Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. J Palliat Med 2012;15:400–403.
82. Strayer RJ, Nelson LS. Adverse events associated with ketamine for procedural sedation in adults. Am J Emerg Med 2008;26:985–1028.
83. Roback MG, Wathen JE, Bajaj L, Bothner JP. Adverse events associated with procedural sedation and analgesia in a pediatric emergency department: a comparison of common parenteral drugs. Acad Emerg Med 2005;12:508–513.
84. Lee SK. The use of ketamine for perioperative pain management. Korean J Anesthesiol 2012;63:1–2.
85. Moore NN, Bostwick JM. Ketamine dependence in anesthesia providers. Psychosomatics 1999;40:356–359.
86. Goyal S, Ambekar A, Ray R. Ketamine dependence in an anesthesiologist: an occupational hazard? Indian J Psychol Med 2014;36:335–337.
87. Goyal S, Agrawal A. Ketamine in status asthmaticus: a review. Indian J Crit Care Med 2013;17:154–161.
88. Morgan CJ, Muetzelfeldt L, Curran HV. Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction 2009;104:77–87.
89. Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction 2010;105:121–133.
90. Chan WH, Sun WZ, Ueng TH. Induction of rat hepatic cytochrome P-450 by ketamine and its toxicological implications. J Toxicol Environ Health 2005;68:1581–1597.
91. Chu PS, Ma WK, Wong SC, et al. The destruction of the lower urinary tract by ketamine abuse: a new syndrome? BJU Int 2008;102:1616–1622.
92. Cottrell A, Warren K, Ayres R, et al. The destruction of the lower urinary tract by ketamine abuse: a new syndrome? BJU Int 2008;102:1178–1179.
93. Muetzelfeldt L, Kamboj SK, Rees H, et al. Journey through the K-hole: phenomenological aspects of ketamine use. Drug Alcohol Depend 2008;95:219–229.
94. Tsai TH, Cha TL, Lin CM, et al. Ketamine-associated bladder dysfunction. Int J Urol 2009;16:826–829.
95. Shahani R, Streutker C, Dickson B, Stewart RJ. Ketamine associated ulcerative cystitis: a new clinical entity. Urology 2007;69:810–812.
96. Selby NM, Anderson J, Bungay P, et al. Obstructive nephropathy and kidney injury associated with ketamine abuse [case report]. NDT Plus 2008;1:310–312.
97. Jhang JF, Hsu YH, Kuo HC. Possible pathophysiology of ketamine-related cystitis and associated treatment strategies. Int J Urol 2015;22:816–825.
98. Morgan CJ, Curran HV. Ketamine use: a review. Addiction 2011;107:27–38.
99. Winstock AR, Mitcheson L, Gillatt DA, Cottrell AM. The prevalence and natural history of urinary symptoms among recreational ketamine users. BJU Int 2012;110:1762–1766.
100. Chung SD, Wang CC, Kuo HC. Augmentation enterocystoplasty is effective in relieving refractory ketamine-related bladder. Neurourol Urodyn 2014;33:1207–1211.
101. Ng SH, Tse ML, Ng HW, Lau FL. Emergency department presentation of ketamine abusers in Hong Kong: a review of 233 cases. Hong Kong Med J 2010;16:6–11.
102. Lee ST, Wu TT, Yu PY, Chen RM. Apoptotic insults to human HepG2 cells induced by S-ketamine occurs through activation of a Bax-mitochondria-caspase protease pathway. Br J Anaesth 2009;102:80–89.
103. Ng SH, Lee HK, Chan YC, Lau FL. Dilated common bile ducts in ketamine abusers. Hong Kong Med J 2009;15:157.
104. Wong SW, Lee KF, Wong J, et al. Dilated common bile ducts mimicking choledochal cysts in ketamine abusers. Hong Kong Med J 2009;15:53–56.
105. Poon TL, Wong KF, Chan MY, et al. Upper gastrointestinal problems in inhalational ketamine abusers. J Dig Dis 2010;11:106–110.
106. Yu WL, Cho CC, Lung PF, et al. Ketamine-related cholangiopathy: a retrospective study on clinical and imaging findings. Abdom Imaging 2014;39:1241–1246.
107. Wong GL, Tam YH, Ng CF, et al. Liver injury is common among chronic abuses of ketamine. Clin Gastroenterol Hepatol 2014;12:1759–1762.
108. Moreton JE, Meisch RA, Stark L, Thompson T. Ketamine self-administration by the rhesus monkey. J Pharmacol Exp Ther 1977;203:303–309.
109. Newman JL, Perry J, Carroll ME. Social stimuli enhance phencyclidine (PCP) self-administration in rhesus monkeys. Pharmacol Biochem Behav 2007;87:280–288.
110. Nicholson KL, Hayes BA, Balster RL. Evaluation of the reinforcing properties and phencyclidine-like discriminative stimulus effects of dextromethorphan and dextrorphan in rats and rhesus monkeys. Psychopharmacology (Berl) 1999;146:49–59.
111. White JM, Ryan CF. Pharmacological properties of ketamine. Drug Alc Review 1996;15:145–155.
112. 11C]raclopride PET study of a model psychosis in humans. J Psychiatr Res 2000;34:35–43.
113. Smith GS, Schloesser R, Brodie JD, et al. Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects. Neuropsychopharmacology 1998;18:18–25.
114. Hancock PJ, Stamford JA. Stereospecific effects of ketamine on dopamine efflux and uptake in the rat nucleus accumbens. Br J Anaesth 1999;82:603–608.
115. Freo U, Ori C. Opioid pharmacology of ketamine. Acta Anaesthesiol Ital 2002;53:149–163.
116. Brent PJ, Chahl LA. Enhancement of the opiate withdrawal response by antipsychotic drugs in guinea-pigs is not mediated by sigma binding sites. Eur Neuropsychopharmacol 1993;3:23–32.
117. Ji D, Sui ZY, Ma YY, et al. NMDA receptor in nucleus accumbens is implicated in morphine withdrawal in rats. Neurochem Res 2004;29:2113–2120.
118. Bree MM, Feller L, Corssen G. Safety and tolerance of repeated anesthesia with CI 581 (ketamine) in monkeys. Anesth Analg 1967;46:596–600.
119. Cumming JF. The development of an acute tolerance to ketamine. Anesth Analg 1976;55:788–791.
120. Byer DE, Gould AB Jr. Development of tolerance of ketamine in an infant undergoing repeated anesthesia. Anesthesiology 1981;54:255–256.
121. Khan MS, Bhatti AH. Ketamine tolerance. Postgrad Med J 1988;64:833–834.
122. Kalsi SS, Wood DM, Dargan Pl. The epidemiology and patterns associated with recreational ketamine use. Emerg Health Threats J 2011;4:7107.
123. Garg A, Sinha P, Kumar P, Prakash O. Use of naltrexone in ketamine dependence. Addict Behav 2014;39:1215–1216.
124. Liu JX, Zerbo E, Ross S. Intensive ketamine use for multiple years: a case report. Am J Addict 2015;24:7.
125. Cheng WC, Ng KM, Chan KK, et al. Roadside detection of impairment under the influence of ketamine—evaluation of ketamine impairment symptoms with reference to its concentration in oral fluid and urine. Forensic Sci Int 2007;170:51–58.
126. Degenhardt L, Dunn M. The epidemiology of GHB and ketamine use in an Australian household survey. Int J Drug Policy 2007;19:311–316.
127. De Luca MT, Meringolo M, Spagnolo PA, Badiani, A. The role of setting for ketamine abuse: clinical and preclinical evidence. Rev Neurosci 2012;23:769–780.
128. Schifano F, Corkery J, Oyefeso A, et al. Trapped in the “K-hole”: overview of deaths associated with ketamine misuse in the UK (1993-2006). J Clin Psychopharmacol 2008;28:114–116.
129. Zhao C, Liu Z, Zhao D, et al. Drug abuse in China. Ann NY Acad Sci 2004;1025:439–445.
130. De la Torre R. Commentary on Morgan et al.(2010): ketamine abuse: first medical evidence of harms we should confront. Addiction 2010;105:134–135.
131. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future National Results on Adolescent Drug Use; Overview of Key Findings, 2011. Ann Arbor: Institute for Social Research, The University of Michigan; 2012.
132. th annual report. Clin Toxicol 2012;50:911–1164.
133. Florida Department of Law Enforcement. Drugs identified in deceased persons by Florida medical examiners. 2011 Report. Available at: https://www.fdle.state.fl.us/Content/getdoc/fa86790e-7b50-45f3-909d-c0a4759fefa8/2011-Drug-Report_Final.aspx
134. Florida Department of Law Enforcement. Drugs identified in deceased persons by Florida medical examiners. 2012 Report. Available at: https://www.fdle.state.fl.us/Content/getdoc/79241c67-253b-45eb-a238-1a07cf4a2a0c/2012-Drug-Report_Final.aspx
135. Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2011: national estimates of drug-related emergency department visits. HHS Publication No. (SMA) 13-4760, DAWN Series D-39. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013.
136. Li JH, Vicknasingam B, Cheung YW, et al. To use or not to use: an update on licit and illicit ketamine use. Subst Abuse Rehabil 2011;2:11–20.
137. Drug Enforcement Agency. Drug fact sheet: ketamine. 2015. Available at: http://www.dea.gov/druginfo/drug_data_sheets/Ketamine.pdf
138. Hill SL, Thomas SH. Clinical toxicology of newer recreational drugs. Clin Toxicol (Phila) 2011;49;705–719.
139. Morris H, Wallach J. From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug Test Anal 2014;6:614–632.
140. Helander A, Beck O, Backberg M. Intoxications by the dissociative new psychoactive substances diphenidine and methoxphenidine. Clin Toxicol (Phila) 2015;53:446–453.
141. Helander A, Backberg M, Hulten P, et al. Detection of new psychoactive substance use among emergency room patients: results from the Swedish STRIDA project. Forensic Sci Int 2014;243:23–29.
142. Backberg M, Beck O, Hulten P, et al. Intoxications of the new psychoactive substance 5-2(aminopropyl) indole (5-IT): a case series from the Swedish STRIDA project. Clin Toxicol (Phila) 2014;52:618–624.